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Neurotransmitter release from preganglionic para-
sympathetic neurons is resistant to inhibition by selec-
tive antagonists of L-, N-, P/Q-, R-, and T-type calcium
channels. In this study, the effects of different -cono-
toxins from genus Conus were investigated on current
flow-through cloned voltage-sensitive calcium channels
expressed in Xenopus oocytes and nerve-evoked trans-
mitter release from the intact preganglionic cholinergic
nerves innervating the rat submandibular ganglia. Our
results indicate that -conotoxin CVID from Conus ca-
tus inhibits a pharmacologically distinct voltage-sensi-
tive calcium channel involved in neurotransmitter re-
lease, whereas -conotoxin MVIIA had no effect.
-Conotoxin CVID and MVIIA inhibited depolarization-
activated Ba2 currents recorded from oocytes express-
ing N-type but not L- or R-type calcium channels. High
affinity inhibition of the CVID-sensitive calcium chan-
nel was enhanced when position 10 of the -conotoxin
was occupied by the smaller residue lysine as found in
CVID instead of an arginine as found in MVIIA. Given
that relatively small differences in the sequence of the
N-type calcium channel 1B subunit can influence
-conotoxin access (Feng, Z. P., Hamid, J., Doering, C.,
Bosey, G. M., Snutch, T. P., and Zamponi, G. W. (2001)
J. Biol. Chem. 276, 15728–15735), it is likely that the
calcium channel in preganglionic nerve terminals tar-
geted by CVID is a N-type (Cav2.2) calcium channel
variant.
Venom of the predatory marine gastropods of the genus
Conus (cone snails) contain a unique array of peptides whose
pharmaceutical potential remains largely unexploited (1).
These peptides have been classified based on their pharmacolog-
ical target and structure (2, 3). One important class, the -cono-
toxins, utilizes a four-loop framework to selectively inhibit “N-
type” voltage-sensitive calcium channels (VSCCs)1 found in the
central and peripheral nervous systems of vertebrates (4).
Neurotransmitter release from preganglionic parasympa-
thetic neurons has been found to be resistant to inhibition by a
range of selective calcium channel antagonists of L-, N-, P/Q-,
R-, and T-type calcium channels (5–8). A recently discovered
-conotoxin from Conus catus (CVID) is highly selective for
N-type over P/Q-type VSCCs (9) and shows potent analgesic
activity in rats (10). In this study, we investigated the effects of
CVID on autonomic neurotransmission using conventional in-
tracellular microelectrode recording techniques. -Conotoxin
CVID was found to be a potent inhibitor of neurally evoked
transmitter release from the intact preganglionic cholinergic
nerves innervating the rat submandibular ganglia, whereas
-conotoxin MVIIA had no effect.
The orientation and nature of the residues in loop 2 of
-conotoxins have been shown to be crucial for selective bind-
ing to the N-type VSCC (11–15). Since the only sequence dif-
ference in loop 2 between CVID and MVIIA is at position 10, we
investigated the importance of this position for -conotoxin
structure and ability to block neurotransmitter release from
preganglionic parasympathetic neurons. The inhibition of
preganglionic transmitter release was favored in -conotoxins
with a Lys at position 10.
EXPERIMENTAL PROCEDURES
Submandibular Ganglia Preparation—2–5-week-old rats were anes-
thetized and killed by cervical fracture prior to the removal of the
submandibular ganglia in accordance with the guidelines of the Uni-
versity of Queensland Animal Experimentation Committee. The sub-
mandibular ganglia were removed as described previously (8, 16). In-
dividual preparations were pinned to the Sylgard (Dow Corning)
covered base of a 2-ml Perspex organ bath. Preparations were contin-
uously perfused at a rate of 2 ml/min with a Krebs phosphate solution
of the following composition (in mM): 118.4 NaCl, 25.0 NaHCO3, 1.13
NaH2PO4, 1.8 CaCl2, 4.7 KCl, 1.3 MgCl2, and 11.1 glucose, gassed with
a mixture of 95% O2 and 5% CO2 to pH 7.4, and maintained at
36–37 °C.
Intracellular Recordings and Analysis—The lingual nerve was field-
stimulated by voltage pulses via bare platinum wires delivered from a
digital stimulator (Pulsar 7, Frederick Haer & Company, Brunswick,
ME) coupled to an optically isolated stimulation unit (Model DS2,
Digitimer Ltd., Welwyn Garden City, United Kingdom). Intracellular
recordings were made from individual ganglion cells using glass micro-
electrodes filled with 5 M potassium acetate (resistances 70–120 mego-
hms). Conventional intracellular recording techniques were used as
described previously (17, 18). Membrane potentials were recorded
through a headstage connected to an Axoclamp-2A amplifier (Axon
Instruments Inc., Union City, CA) in bridge mode and stored on a
digital audio tape using a digital tape recorder (DTR-1204, BioLogic
Science Instruments, Claix, France). Evoked events were digitized at
5–10 kHz and transferred to a computer using an analogue-to-digital
converter (Digidata 1200A interface) and Axotape software (Axon In-
struments Inc.). The amplitude, frequency, rise time, and latency of
evoked and spontaneous events were analyzed using Axograph 2 (Axon
Instruments Inc.). The mean resting membrane potential of the sub-
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mandibular ganglion neurons was 63.8  0.6 mV (n  52). The mean
base line was determined by averaging the initial part of the digitized
signal between the stimulus artifact and the onset of the response. Data
are expressed as the mean  S.E., and n values refer to the number of
preparations. Data were analyzed statistically using Student’s paired t
test with the level of significance being taken as p  0.05.
Electrophysiological Recording of Recombinant Ca2 Channel Cur-
rents in Xenopus Oocytes—Capped RNA transcripts encoding full-
length rat 1B and 3 (a gift of D. Lipscombe, Brown University) and
rabbit 1C and 2 (a gift of G. Zamponi, University of Calgary) were
synthesized using a mMESSAGE mMachine in vitro transcription kit
(Ambion). Xenopus laevis stage V–VI oocytes were removed and treated
with collagenase (Sigma type I) for defolliculation. For N- or L-type
Ca2 channel expression, the oocytes were then injected with cRNA
mixtures of either 1B (2.5 ng/cell) or 1C (5 ng/cell) in combination with
2 and 3 in the ratio of 1:1:1 or 1:2.5:1, respectively. For R-type Ca
2
channels, cDNA for rat 1E (4.5 ng/cell) (a gift of G. Zamponi, University
of Calgary) was injected intranuclearly in combination with the cRNA
injection of 2 and 3 (2.5 ng/cell each). The oocytes were incubated at
18 °C in ND96 solution (in mM): 96 NaCl, 2 KCl, 1 CaCl2, 1 MgCl2, 5
HEPES, 5 pyruvic acid, and 50 g/ml gentamicin, pH 7.5, prior to
recording. 3–8 days after cRNA/cDNA injection, whole cell Ca2 chan-
nel currents were recorded from oocytes using the two-electrode (virtual
ground circuit) voltage clamp technique. Microelectrodes were filled
with 3 M KCl and typically had resistances of 0.31.5 megohms. All
recordings were made at room temperature (2023 °C) using bath
solution containing the following components (in mM): 5 BaCl2, 85
tetraethylammonium hydroxide, 5 KCl, and 5 HEPES titrated to pH 7.4
with methansulfonic acid. During recording, oocytes were perfused
continuously at a rate of 1.5 ml/min. The activation of Cl current by
Ba2 influx through the Ca2 channel was eliminated by injecting 50 nl
of 50 mM BAPTA-Na4 at least 15 min prior to recording. Using a
GeneClamp 500B amplifier and pCLAMP 8 software (Axon Instru-
ments Inc.), data were acquired at 10 kHz after low pass filtration at 1
kHz and leak-subtracted on-line using a P/4 protocol and analyzed.
Currents were evoked with 100-ms depolarizing pulses to 0 mV from a
holding potential of 80 mV at 20-s intervals. Peak current was meas-
ured before and during the perfusion of -conotoxins and antagonists
for up to 10 min.
Radioligand Binding—Preparation of rat brain membrane and
[125I]GVIA and radioligand displacement protocols were as described
previously (9, 14, 15).
-Conotoxin Synthesis—-Conotoxins CVID, [K10R]CVID, MVIIA,
[R10K]MVIIA, and [Y13F]CVID were assembled by manual stepwise
synthesis using in situ neutralization with Boc chemistry (19). Starting
from methylbenzhydrylamine HCl resin (0.5-mmol scale), 4 eq of Boc-
protected amino acids were coupled to the growing chain using 4 eq of
0.5 M HBTU in N,N-dimethylformamide and 5 eq of N,N-diisopropyl-
ethylamine. The side chain protection chosen was Arg(Tos), Asp(O-
cHex), Lys(CIZ), Thr(Bzl), Tyr(BrZ), Ser(Bzl), and Cys(p-MeBzl). The
chain assembly was monitored after each step by the quantitative
ninhydrin method and double-coupled when coupling yields were
99.7%. The capping of the remaining amino groups by acetylation was
FIG. 1. Effect of-conotoxin CVID on nerve-evoked EPSPs and
spontaneous EPSPs in the rat submandibular ganglion. A, con-
trol EPSPs evoked by trains of 10 stimuli at 1 Hz. B, postsynaptic
responses evoked 20 min after the bath application of 30 nM CVID. C,
postsynaptic responses evoked 20 min after the bath application of 300
nM CVID. Inset, effect of CVID (100 nM) on spontaneous EPSPs. D,
dose-response relationship obtained for the effects of the calcium chan-
nel antagonists, -conotoxin CVID, -conotoxin GVIA, -conotoxin
MVIIA, -grammotoxin SIA, and -agatoxin IVA on EPSP peak ampli-
tude. The solid lines represent the best fit of the data for each toxin.
FIG. 2. Effect of [K10R]CVID, -conotoxin MVIIA, and
[R10K]MVIIA on EPSPs in the rat submandibular ganglion. EP-
SPs were evoked by trains of 10 stimuli at 0.5 Hz. A, 10 superimposed
traces in the absence (control) and presence of 100 nM [K10R]CVID. B,
10 superimposed traces in the absence (control) and presence of 100 nM
MVIIA. C, 10 superimposed traces in the absence (control) and presence
of 100 nM [R10K]MVIIA. D, histogram of the percentage inhibition of
EPSP amplitude by equivalent concentrations (100 nM) of CVID,
[K10R]CVID, MVIIA, and [R10K]MVIIA.
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performed using acetic anhydride in N,N-dimethylformamide (87 l/
ml). After assembly, side chain-protecting groups were removed and the
peptide was concurrently cleaved from the resin using anhydrous hy-
drogen fluoride/p-cresol/p-thiocresol (18:1:1). The peptides were puri-
fied and oxidized as described previously (15). Mass spectra were meas-
ured on a time-of-flight mass spectrometer (PerSeptive Biosystems)
equipped with an electrospray atmospheric pressure ionization (ESI)
source. Boc-L-amino acids were obtained from Auspep (Melbourne,
Australia). Methylbenzhydrylamine HCl (0.79 mmol/g) was obtained
from Peptide Institute (Osaka, Japan). HBTU was obtained from Rich-
elieu Biotechnologies (Quebec, Canada). Trifluoroacetic acid, N,N-
dimethylformamide, and N,N-diisopropylethylamine were of peptide
synthesis grade and purchased from Auspep. Acetonitrile and methanol
(Hypersolve Far-UV grade) were from BDH (Poole, United Kingdom).
Hydrogen fluoride was supplied by Boc Gases (Brisbane, Australia). All
other chemicals were of analytical grade from commercial suppliers.
1H NMR Spectroscopy—All NMR spectra were recorded on a Bruker
ARX 500 spectrometer equipped with a z-gradient unit or on a Bruker
DMX 750 spectrometer equipped with a x,y,z-gradient unit. Peptide
concentrations were 2 mM. H chemical shifts for the native peptides
and the two analogues were obtained from spectra recorded in 95%
H2O, 5% D2O, pH 3.0–3.5, at 293 K. Restraints for three-dimensional
structure calculations were obtained from spectra recorded at 293 K
with additional experiments run at 280 K to resolve overlapping signal
(15). Secondary H chemical shifts were analyzed compared with the
random coil shift values of Wishart et al. (20), and structures were
calculated using torsion angle dynamics/simulated annealing protocol
in XPLOR version 3.8 (21–24) as previously described (14).
Drugs—Drugs were dissolved in the Krebs phosphate solution per-
fusing the preparation, and the effects were evaluated after they
reached equilibrium (20 min). The dose-response relations were de-
termined for -conotoxins, whereas other drugs were bath-applied at a
maximally effective concentration. In addition to the synthesized
-conotoxins, we tested -agatoxin IVA, -conotoxin GVIA, -conotoxin
MVIIC (Alamone Laboratories, Jerusalem, Israel), SNX-482 (Peptide
Institute Inc., Osaka, Japan), cadmium chloride, hexamethonium,
mecamylamine, nifedipine, and tetrodotoxin (Sigma). -Grammotoxin
SIA was a kind gift from Dr. Rick Lampe (Zeneca Pharmaceuticals,
Wilmington, DE).
RESULTS
Characteristics of Excitatory Postsynaptic Potentials (EPSPs)—
Stimulation of the lingual nerve with trains of stimuli (0.1–10 Hz,
4–50 V, pulse-width 0.05–0.25 ms) evoked EPSPs, which could
initiate action potentials in the cell bodies of the postsynaptic neu-
rons of the rat submandibular ganglion. The postganglionic neu-
rons have been classified into three types by their responses to
these trains of stimuli (8). In this study, neurons in which supra-
maximal stimulation of the preganglionic nerve fibers at 0.1 Hz
either evoked a suprathreshold EPSP and action potential in re-
sponse to every stimulus (strong input synapse, 50% of total
number of neurons) (Fig. 1A) or where the EPSP does not usually
reach threshold for the initiation of an action potential (weak input
synapse,  25% of neurons studied) were used. EPSPs recorded
from neurons receiving either strong or weak inputs were abolished
by hexamethonium (100M) and mecamylamine (10M) indicating
that EPSPs were mediated by acetylcholine acting at nicotinic
receptors.
Effects of Calcium Channel Inhibitors on EPSPs—-Cono-
toxin CVID produced a reversible and concentration-dependent
inhibition of EPSPs (Fig. 1). Control EPSPs from both strong
and weak input neurons had a mean amplitude of 26.2  2.5
mV, and 20 min after bath application of CVID (100 nM), these
EPSPs were reduced by 66% to a mean amplitude of 9.1  1.1
mV (n  13). The IC50 for inhibition of the CVID-sensitive
component (79 8% of peak amplitude) was 32 nM (pIC50 7.5
0.15). CVID had no detectable effect on the resting membrane
potential of individual ganglion cells or on the amplitude and
frequency of spontaneous EPSPs (n 5) (Fig. 1, inset), suggest-
ing that it acted presynaptically to inhibit neurally evoked
transmitter release. To confirm that Tyr-13 in loop 2 contrib-
utes significantly to the ability of CVID to inhibit transmitter
release, we assessed the potency of the phenylalanine analogue
of CVID on transmitter release. [Y13F]CVID (0.1–1 M) was
without effect on the EPSPs (n  3).
The effect of CVID contrasts with the effects of 300 nM
-conotoxin GVIA (N-type), 100 nM -agatoxin IVA, 300 nM
-conotoxin MVIIC (P/Q-type), 300 nM -grammotoxin SIA,
300 nM SNX-482 (R-type), and 30 M nifedipine (L-type), which
had little or no inhibitory effect on evoked and spontaneous
transmitter release in rat submandibular ganglia either alone
or in combination with each other (n 3–13 per drug) (Fig. 1D),
TABLE I
Sequences and potencya of synthetic -conotoxins
CVID, a conotoxin from Conus catus; MVIIA, a conotoxin from Conus magus; GVIA, a conotoxin from Conus geographus; O, hydroxyproline.
Peptide Sequence pIC50 (95% CI)
CVID CKSKGAKCSKLMYDCCTGSCSGTVGRCb 10.42 (0.10)
[K10R] CVID CKSKGAKCSRLMYDCCTGSCSGTVGRCb 10.81 (0.13)
[Y13F] CVID CKSKGAKCSKLMFDCCTGSCSGTVGRCb 7.79 (0.042)
MVIIA CKGKGAKCSRLMYDCCTGSCRS–GKCb 10.65 (0.16)
[R10K] MVIIA CKGKGAKCSKLMYDCCTGSCRS–GKCb 10.62 (0.046)
GVIA CKSOGSSCSOTSYNCCR-SCNOYTKRCYb 10.63 (0.17)
a Potency presented as the pIC50 (logIC50) for displacement of [
125I]GVIA from rat brain membrane.
b Amidated C terminus.
TABLE II
Specificity of calcium channel antagonists to inhibit VSCC subtypes and nerve-evoked transmitter release from
rat preganglionic
nerve terminals
Evidence for VSCC inhibition (), no inhibition (), or unknown (?) are indicated. Numbers of replicate experiments (n) in the present study or
reference numbers are shown.
VSCC antagonist Transmitterrelease 1A (P/Q type) 1B (N-type) 1C (L-type) 1E (R-type)
-CVID  (n  13)  (9)  (n  5) (9)  (n  3)  (n  4)
-MVIIA  (n  5)  (9)  (n  5) (9, 31)  (n  3)  (n  4)
-GVIA  (n  9)  (29)  (30, 31)  (32)  (33)
-MVIIC  (n  5)  (29, 30)  (30) ?  (34)
-agatoxin IVA  (n  4)  (29, 30)  (30, 31)  (32)  (33, 34)
-grammotoxin SIA  (n  8)  (30)  (28, 30)  (28) ?
SNX-482  (n  4)  (35)  (28, 35)  (28)  (28, 35)
Nifedipine  (n  8)  (36)  (n  3) (31, 36)  (32, 36)  (36)
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confirming previous results (8). In a proportion of weak input
neurons, GVIA inhibited EPSPs by up to 12% of the control
amplitude (5 of 8 preparations) (Fig. 1D) with an IC50 of 60 nM,
suggesting that GVIA-sensitive calcium channels play a minor
role in neurotransmission in the rat submandibular ganglia.
GVIA had no effect on strong input neurons (n  4). EPSPs
were consistently abolished by low concentrations of the non-
specific calcium channel blocker Cd2 (30 M, n 8), indicating
that neurally evoked transmitter release from preganglionic
neurons was dependent on calcium influx through VSCCs.
Of the characterized -conotoxins, CVID most closely resem-
bles MVIIA in structure. Despite this structural similarity,
MVIIA (10–1000 nM) failed to produce detectable inhibition of
EPSPs (n  4) (Fig. 2B). Since loop 2 contributes mostly to
-conotoxin potency at N-type VSCCs, we investigated the
influence of a Lys/Arg swap at position 10 in CVID and MVIIA
on their ability to block neurotransmitter release. Bath appli-
cation of a maximally effective concentration of [K10R]CVID
(100 nM) produced only 19% inhibition of EPSPs (Fig. 2A),
reducing control EPSPs of 27.6 2.9 mV to 22.4 2.2 mV after
20 min (n  8). In contrast to the ineffective MVIIA,
[R10K]MVIIA caused a 47% inhibition of EPSP amplitude (Fig.
2C), reducing control EPSPs from 27.0  2.4 mV to 14.4  2.2
mV after 20 min (n 6). [R10K]MVIIA had no detectable effect
on the membrane potential of individual ganglion neurons or
on the amplitude and frequency of spontaneous EPSPs (data
not shown), suggesting that similar to CVID, it acted presyn-
aptically to inhibit evoked neurotransmitter release.
The effects of -conotoxin GVIA (100 nM), -agatoxin IVA
(100 nM), -conotoxin MVIIC (100 nM), -grammotoxin SIA
(100 nM), SNX-482 (100 nM), and nifedipine (10 M) were also
investigated on the CVID-resistant transmitter release. These
toxins, applied alone or in combination with each other, had no
detectable effects on the transmitter release recorded in the
presence of 100 nM CVID (n  3 for each toxin).
Radioligand Binding Studies—The affinity of -conotoxins
CVID, MVIIA, and their analogues for N-type VSCCs was
determined from their ability to displace [125I]GVIA from rat
brain membrane. The pIC50 values are shown in Table I.
[K10R]CVID and [R10K]MVIIA had potencies that were com-
parable with the native peptides. However, [Y13F]CVID was
significantly less potent than CVID, confirming that the hy-
droxyl group in Tyr-13 of CVID has a similar influence on
binding to the N-type VSCC as seen previously for the Y13F
analogues of GVIA and MVIIA (25).
Effect of -Conotoxins on Recombinant Ca2 Channels Ex-
pressed in Xenopus Oocytes—The effect of -conotoxins CVID
and MVIIA were examined on L-, N-, and R-type Ca2 channels
expressed in Xenopus oocytes. Whole cell Ca2 channel cur-
rents were recorded from oocytes injected with either rat cRNA
or cDNA for 1B, 1C, or 1E in combination with 2 and 3
using 5 mM Ba2 as the charge carrier. Bath application of
either -conotoxins CVID or MVIIA (300 nM) inhibited the
depolarization-activated inward Ba2 current recorded from
oocytes expressing N-type but had no effect on current through
L- or R-type Ca2 channels (see Table II) (29–36). The inhibi-
tion of Ba2 currents through N-type Ca2 channels by -cono-
toxin CVID and MVIIA was dose-dependent and slowly re-
versed upon washout.
Three Dimensional Structures—H chemical shifts relative
to random coil values are a sensitive measurement of backbone
conformation for disulfide-bonded isomers and can be used to
locate local conformational differences across structurally re-
lated peptides (25, 26). H chemical shifts were similar for
[K10R]CVID and [R10K]MVIIA compared with the native pep-
tides CVID and MVIIA (Fig. 3A), indicating that any global
structural changes on swapping residue 10 are minimal. The
three-dimensional structure of [R10K]MVIIA differed from
MVIIA by a root mean square deviation of 0.461 across the
heavy backbone atoms, confirming the absence of any signifi-
cant structural change. This is seen in the ribbon diagram
showing the superimposition of the 17 lowest energy conforma-
tions and the orientation of Tyr-13 and Lys/Arg-10 for CVID,
MVIIA, and [R10K]MVIIA (Fig. 3B). To determine whether the
difference in selectivity might arise from difference surface
exposure at position 10, we calculated the solvent-accessible
FIG. 3. Three-dimensional structures of -conotoxins CVID,
MVIIA, and [R10K]MVIIA. A, H chemical shifts for -conotoxins
CVID, [K10R]CVID, MVIIA, and [R10K]MVIIA at 293 K in 95% H2O,
5% D2O. Residue numbers are labeled according to the CVID sequence.
B, ribbon diagrams of the backbones for CVID (i), MVIIA (ii), and
[R10K]MVIIA (iii). The 17 lowest energy conformations of the side
chains at positions 10 (Lys or Arg) and 13 (Tyr) are also shown on the
left side. On the right side are shown the ribbon diagrams rotated 180o
around the y axis and the calculated Connolly surface area of Lys/
Arg-10 and the orientation of Tyr-13 in loop 2 (residues 8–14 are
shown). Structures of the lowest energy conformation were superim-
posed over backbone atoms C, C, and N (1–27 and 1–25) for CVID,
MVIIA, and [R10K]MVIIA, respectively (Insight II 2000).
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surface area for residue 10 over the 17–20 lowest energy con-
formations in Insight II. The rank order of the solvent-accessi-
ble surface area was MVIIA  [R10K]MVIIA  CVID (156 
8.0, 147  8.1, and 92  4.6 Å2, respectively). A complete
three-dimensional structure was not calculated for
[K10R]CVID, because it had the same potency at the N-type
VSCC and conserved H chemical shift differences compared
with CVID especially across loop 2 (Fig. 3A).
DISCUSSION
Neurotransmitter release from the preganglionic cholinergic
neurons innervating the rat submandibular ganglia is resist-
ant to inhibition by commonly used selective antagonists of N-,
L-, P/Q-, R-, and T-type calcium channels (8, 17). The aim of
this study was to investigate the effects of the recently identi-
fied -conotoxin CVID, the most selective N-type versus P/Q-
type VSCC blocker, on transmitter release from these nerve
terminals. CVID (IC50  32 nM) produced up to 80% inhibition
of nerve-evoked transmitter release without affecting sponta-
neous transmitter release, and this inhibition was reversed
upon washout. In contrast, nerve-evoked transmitter release
was unaffected by MVIIA (1 M). Interestingly, the potency of
CVID to inhibit transmitter release from preganglionic cholin-
ergic neurons was similar to the potency of both CVID and
MVIIA to inhibit N-type VSCCs in postganglionic sympathetic
neurons of rat vas deferens (9).
Loop 2 of -conotoxins has been identified as the primary
loop involved in binding to the N-type VSCC (11, 13, 25) with
the hydroxyl group on Tyr-13 on both -conotoxin GVIA and
MVIIA found to be a critical determinant of high interaction at
the N-type VSCC (12, 27). The 400-fold reduction in potency of
[Y13F]CVID for rat brain N-type VSCC confirmed a key role of
Tyr-13 in CVID. [Y13F]CVID was also inactive on the EPSPs,
indicating that N-type and CVID-sensitive VSCCs both require
the hydroxyl of Tyr-13. One possible conclusion from this result
is that CVID may bind to both VSCCs in a similar manner.
Because loop 2 of MVIIA and CVID vary only at position 10
(Lys or Arg, respectively) (see Table. 1), we investigated the
role of this position contributing to the selectivity differences
observed between MVIIA and CVID by swapping these resi-
dues. [K10R]CVID (100 nM) produced significantly less ( 20%)
inhibition of transmitter release than CVID, indicating that
Lys-10 was the preferred residue for resistant-type VSCC in-
hibition by CVID. Supporting this conclusion, Lys-10 was
found to markedly enhance MVIIA inhibition of resistant-type
VSCCs with the [R10K]MVIIA (100 nM) causing 47% inhibition
of evoked transmitter release (i.e. 100-fold more than
MVIIA). None of the -conotoxins investigated affected spon-
taneous transmitter release or the resting membrane potential
of the postsynaptic cell, indicating a selective action at presyn-
aptic VSCCs.
The effects of the L-, N-, P/Q-, and R-type VSCC antagonists
(nifedipine, -conotoxin GVIA, -conotoxin MVIIC, -agatoxin
IVA, -grammotoxin SIA, and SNX-482) were investigated on
the transmitter release remaining after the application of
CVID. None of these VSCC inhibitors, either applied alone or in
combination, had any effect on the CVID-resistant neurotrans-
mitter release. However, the CVID-resistant release was re-
versibly abolished by Cd2, indicating its dependence on cal-
cium entry into nerve terminals through VSCCs. Because the
R-type VSCC inhibitors used do not inhibit all R-type VSCCs
(28), we investigated the effects of -conotoxins CVID and
MVIIA on current flow-through cloned L- or R-type calcium
channels expressed in Xenopus oocytes. Both CVID and MVIIA
had no effect on depolarization-activated Ba2 currents
through L- or R-type calcium channels but potently inhibited
current through N-type VSCCs (see Table II) as reported
previously (9).
In an attempt to understand the structural basis of the
selectivity differences between -conotoxin MVIIA and
[R10K]MVIIA at the CVID-sensitive VSCCs, we determined
their secondary and tertiary structures by 1H NMR. From
these studies, it was evident that residue replacements at
position 10 had little effect on the global fold or structure of
CVID or MVIIA. However, examining the solvent-accessible
surface area at position 10 revealed a trend of decreasing
surface area that correlated with activity at the CVID-sensitive
VSCCs in preganglionic neurons. It is possible that the degree
of exposure may influence the selectivity of -conotoxins with
the most exposed residue, Arg in MVIIA, creating a clash that
precludes binding to certain VSCCs. Recently, Feng et al. (37)
identified that a single residue change on an extracellular loop
of the N-type VSCC (G1326) can influence -conotoxin access.
Thus, relatively small differences in N-type VSCC sequence
may significantly alter -conotoxin affinity, raising to the pos-
sibility that the VSCC targeted by CVID in preganglionic nerve
terminals may be a N-type (Cav2.2) calcium channel variant
that does not bind all -conotoxins. Two functionally distinct
variants of the 1B subunit, 1B-b and 1B-d, of the N-type
calcium channel that differ at two loci (four amino acids
(SFMG) in IIIS3–S4 and two amino acids (Glu/Thr) in IVS3–
S4) have been shown to be reciprocally expressed in rat brain
and sympathetic ganglia (38). The selective expression of phar-
macologically distinct VSCC splice variants of 1B subunits in
different regions of the nervous system is proposed to underlie
the differential block of preganglionic nerve terminal VSCCs by
N-type selective -conotoxins. Alternative splicing of the do-
main II–III linker region of the human N-type (Cav2.2) calcium
channel 1B subunit has recently been shown to differentially
affect -conotoxin MVIIA and GVIA block of the calcium chan-
nel current (39).
In conclusion, CVID was found to be a potent inhibitor of the
pharmacologically distinct VSCC controlling a major compo-
nent of transmitter release in preganglionic cholinergic nerve
terminals. CVID may help to define the nature and role of this
VSCC. Position 10 appears to play a key role in influencing
-conotoxin affinity for this N-type-related VSCC. Given that
[125I]CVID labels fewer sites in rat brain than [125I]MVIIA (9),
it is unlikely that these resistant-type VSCCs are among the
high voltage-activated VSCCs labeled by [125I]-Aga-IIIA in
rat brain (40). Intrathecal CVID (AM336) and MVIIA (Zi-
conotide) are currently being evaluated clinically as treatments
for severe pain (10, 41). Because parasympathetic nerves arise
from spinal cord neurons, it is possible that CVID-sensitive
VSCCs are also expressed and play a role in neurotransmission
in the spinal cord. Given the differences in the selectivity of
-conotoxin CVID and MVIIA for this VSCC subtype, these
-conotoxins may have different profiles of activity in the cen-
tral (for review see Refs. 10 and 42) as well as the peripheral
nervous system.
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